Published in PLoS One on November 27, 2012
Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009. PLoS One (2013) 0.82
Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine. PLoS One (2014) 0.81
Effect of AcHERV-GmCSF as an Influenza Virus Vaccine Adjuvant. PLoS One (2015) 0.77
Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1. PLoS One (2016) 0.76
Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge. PLoS One (2015) 0.75
Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development. Sci Rep (2015) 0.75
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Immunologic basis of vaccine vectors. Immunity (2010) 1.71
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
Human papillomavirus vaccines: current status and future prospects. Drugs (2010) 1.33
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis (1996) 1.19
Vaccine delivery methods using viral vectors. Mol Pharm (2007) 1.17
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine (2004) 1.17
Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol (2011) 1.17
Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer (2011) 1.16
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther (2011) 1.12
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol (2006) 1.08
DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines (2008) 1.04
Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine (2001) 0.99
Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther (2012) 0.98
Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol (2004) 0.96
Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge . Vaccine (1997) 0.96
The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer (2010) 0.94
Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model. Viral Immunol (2006) 0.92
Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol (2011) 0.87
Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine (2009) 0.85
Advances in viral-vector systemic cytokine gene therapy against cancer. Vaccine (2010) 0.84
Advances in human papilloma virus vaccines: a patent review. Expert Opin Ther Pat (2011) 0.83
Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine (2010) 0.83
Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy (2011) 0.79
Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16L1 protein and DNA as a vaccine co-delivery system. Biomaterials (2011) 0.79
Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release (2009) 1.81
siRNA conjugate delivery systems. Bioconjug Chem (2009) 1.69
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release (2007) 1.20
Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release (2009) 1.17
Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis. J Control Release (2002) 1.15
Alterations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II. Biochim Biophys Acta (2002) 1.06
Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS One (2010) 1.05
Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials (2009) 1.05
Accelerated cerebral ischemic injury by activated macrophages/microglia after lipopolysaccharide microinjection into rat corpus callosum. Glia (2005) 1.04
Differential expression and polarized secretion of CXC and CC chemokines by human intestinal epithelial cancer cell lines in response to Clostridium difficile toxin A. Microbiol Immunol (2002) 1.04
Vacuolating cytotoxin in Helicobacter pylori water-soluble proteins upregulates chemokine expression in human eosinophils via Ca2+ influx, mitochondrial reactive oxygen intermediates, and NF-kappaB activation. Infect Immun (2007) 1.02
CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-kappaB-independent pathways. Int Immunol (2005) 1.02
Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release (2009) 1.00
Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects. Int J Pharm (2005) 1.00
Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers (2008) 0.98
Topical application of porcine placenta extract inhibits the progression of experimental contact hypersensitivity. J Ethnopharmacol (2010) 0.97
Helicobacter pylori infection activates NF-kappaB signaling pathway to induce iNOS and protect human gastric epithelial cells from apoptosis. Am J Physiol Gastrointest Liver Physiol (2003) 0.96
Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm (2007) 0.95
Effects of transcription factor activator protein-1 on interleukin-8 expression and enteritis in response to Clostridium difficile toxin A. J Mol Med (Berl) (2007) 0.95
Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm (2013) 0.94
Bacteroides fragilis enterotoxin induces cyclooxygenase-2 and fluid secretion in intestinal epithelial cells through NF-kappaB activation. Eur J Immunol (2006) 0.94
Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. Eur J Pharm Sci (2004) 0.93
Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Release (2010) 0.93
Safety and tumor tissue accumulation of pegylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer. Biomaterials (2013) 0.93
Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine (2010) 0.93
Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release (2010) 0.91
Bacteroides fragilis enterotoxin induces human beta-defensin-2 expression in intestinal epithelial cells via a mitogen-activated protein kinase/I kappaB kinase/NF-kappaB-dependent pathway. Infect Immun (2010) 0.91
Effect of sodium chloride on the release, absorption and safety of diclofenac sodium delivered by poloxamer gel. Int J Pharm (2003) 0.90
Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J Neurochem (2006) 0.89
In vivo imaging of tumor apoptosis using histone H1-targeting peptide. J Control Release (2010) 0.89
Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol (2003) 0.89
Outer membrane protein H for protective immunity against Pasteurella multocida. J Microbiol (2007) 0.88
Antifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acid. Mol Ther (2010) 0.88
Low molecular weight polyethylenimine for efficient transfection of human hematopoietic and umbilical cord blood-derived CD34+ cells. Biochim Biophys Acta (2005) 0.88
Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials (2005) 0.88
Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol Ther (2013) 0.87
HAUSP, a deubiquitinating enzyme for p53, is polyubiquitinated, polyneddylated, and dimerized. FEBS Lett (2005) 0.87
Ciclopirox protects mitochondria from hydrogen peroxide toxicity. Br J Pharmacol (2005) 0.86
Plasmid vectors harboring cellular promoters can induce prolonged gene expression in hematopoietic and mesenchymal progenitor cells. Biochem Biophys Res Commun (2005) 0.86
Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials (2011) 0.86
In situ gelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA. J Biomed Mater Res (2002) 0.86
Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery. Biomaterials (2013) 0.86
A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol Pharm (2011) 0.86
Comparison of maturation, fertilization, development, and gene expression of mouse oocytes grown in vitro and in vivo. J Assist Reprod Genet (2004) 0.85
Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med (Berl) (2006) 0.85
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm (2011) 0.85
Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine (2009) 0.85
The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer (2011) 0.84
Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release (2010) 0.84
Biodistribution and tissue expression kinetics of plasmid DNA complexed with polyethylenimines of different molecular weight and structure. J Control Release (2006) 0.84
Upregulation of RhoB via c-Jun N-terminal kinase signaling induces apoptosis of the human gastric carcinoma NUGC-3 cells treated with NSC12618. Carcinogenesis (2010) 0.83
Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine (2007) 0.83
Skin permeation, biodistribution, and expression of topically applied plasmid DNA. J Gene Med (2004) 0.83
Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES. Virology (2003) 0.83
Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J Gene Med (2009) 0.83
DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway. J Cell Biochem (2008) 0.83
Maltose binding protein facilitates high-level expression and functional purification of the chemokines RANTES and SDF-1alpha from Escherichia coli. Protein Expr Purif (2008) 0.83
pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J Pharm Pharmacol (2002) 0.83
Studying changes in the incidence, diagnosis and management of GTD: the South Korean model. J Reprod Med (2004) 0.83
Advances in human papilloma virus vaccines: a patent review. Expert Opin Ther Pat (2011) 0.83
Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009. PLoS One (2013) 0.82
Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect. Pharm Res (2013) 0.82
In situ dose amplification by apoptosis-targeted drug delivery. J Control Release (2011) 0.82
Analysis of the complete nucleotide sequence of a white spot syndrome virus isolated from Pacific white shrimp. J Microbiol (2013) 0.82
Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS). Eur J Pharm Biopharm (2011) 0.82
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials (2012) 0.82
Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm Res (2011) 0.81
Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides. Biomaterials (2008) 0.81
Dual effects of Helicobacter pylori vacuolating cytotoxin on human eosinophil apoptosis in early and late periods of stimulation. Eur J Immunol (2010) 0.81
Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing. Biochem Biophys Res Commun (2008) 0.81
Recombinant human erythropoietin produced in milk of transgenic pigs. J Biotechnol (2006) 0.81
Mimosine prevents the death of glucose-deprived immunostimulated astrocytes by scavenging peroxynitrite. Glia (2002) 0.81
Preclinical pharmacokinetics and biodistribution of human papillomavirus DNA vaccine delivered in human endogenous retrovirus envelope-coated baculovirus vector. Pharm Res (2011) 0.81
Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel. Int J Pharm (2006) 0.81
Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods (2006) 0.81
Cloning and characterization of 5'-untranslated region of porcine beta casein gene (CSN2). Domest Anim Endocrinol (2008) 0.80
Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch Pharm Res (2009) 0.80
Enhanced cellular delivery and transfection efficiency of plasmid DNA using positively charged biocompatible colloidal gold nanoparticles. Biochim Biophys Acta (2007) 0.80
Effect of process parameters on nanoemulsion droplet size and distribution in SPG membrane emulsification. Int J Pharm (2010) 0.80
Analysis of natural recombination in porcine endogenous retrovirus envelope genes. J Microbiol Biotechnol (2008) 0.80
Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J Drug Target (2009) 0.80
Inhibition of Helicobacter pylori-induced nuclear factor-kappa B activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells. Helicobacter (2003) 0.80
Assessment of siRNA pharmacokinetics using ELISA-based quantification. J Control Release (2009) 0.80
Nrf2 is essential for the expression of lipocalin-prostaglandin D synthase induced by prostaglandin D2. Free Radic Biol Med (2013) 0.80
Anionic amino acid-derived cationic lipid for siRNA delivery. J Control Release (2009) 0.80
Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16L1 protein and DNA as a vaccine co-delivery system. Biomaterials (2011) 0.79